DOCSLIB.ORG

Regulation of Osteoclastogenesis by Mast

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Regulation of Osteoclastogenesis by Mast Kim et al. Arthritis Research & Therapy (2021) 23:124 https://doi.org/10.1186/s13075-021-02491-1 RESEARCH ARTICLE Open Access Regulation of osteoclastogenesis by mast cell in rheumatoid arthritis Kyoung-Woon Kim1, Bo-Mi Kim2, Ji-Yeon Won1, Hong-Ki Min3, Kyung-Ann Lee4, Sang-Heon Lee3 and Hae-Rim Kim3* Abstract Background: In the pathogenesis of rheumatoid arthritis (RA), the role of mast cells has not been revealed clearly. We aimed to define the inflammatory and tissue-destructive roles of mast cells in rheumatoid arthritis (RA). Methods: Serum and synovial fluid (SF) concentration levels of tryptase, chymase, and histamine were quantified using ELISA. After activating mast cells using IL-33, the production of TNF-α,IL-1β, IL-6, IL-17, RANKL, and MMPs was determined using real-time PCR and ELISA. Osteoclastogenesis was assessed in CD14+ monocytes from peripheral blood and SF, which were cultured with IL-33-activated mast cells, by counting TRAP-positive multinucleated cells. Results: The concentration levels of serum tryptase, chymase, and histamine and SF histamine were higher in patients with RA than in controls. FcεR1 and c-kit-positive mast cells were higher in RA synovium than in osteoarthritic (OA) synovium. Stimulation of mast cells by IL-33 increased the number of trypatse+chymase− and tryptase+chymase+ mast cells. IL-33 stimulation also increased the gene expression levels of TNF-α,IL-1β, IL-6, IL-17, RANKL, and MMP-9 in mast cells. Furthermore, IL-33 stimulated human CD14+ monocytes to differentiate into TRAP+ multinucleated osteoclasts. When CD14+ monocytes were co-cultured with mast cells, osteoclast differentiation was increased. Additionally, IL-33- activated mast cells stimulated osteoclast differentiation. The inhibition of intercellular contact between mast cells and monocytes using inserts reduced osteoclast differentiation. Conclusions: IL-33 increased inflammatory and tissue-destructive cytokines by activation of mast cells. Mast cells stimulated osteoclast differentiation in monocytes. Mast cells could stimulate osteoclastogenesis indirectly through production of tissue-destructive cytokines and directly through stimulation of osteoclast precursors. Keywords: Rheumatoid arthritis, Mast cell, Osteoclast, Cytokine Background Mast cells, which are typically found in allergic diseases, Rheumatoid arthritis (RA) is characterized by intercellular are also found in RA synovial tissues and synovial fluid interactions between macrophages, lymphocytes, synovial (SF). They are also known to be involved in RA pathogen- fibroblasts, osteoclasts, and chondrocytes, resulting in esis. In RA, the synovium shows hyperplasia of mast cells, chronic inflammation and joint destruction [1]. Although which can comprise up to 5% of all RA synovial cells. The the roles of most of these cells in RA pathogenesis are number of mast cells in RA synovium is higher than that well-studied, mast cells and basophils remain important in osteoarthritic synovium [3]. Mast cells are mainly found exceptions [2]. around blood vessels, in the sublining area, and in areas of cartilage erosion. There are 2 types of mast cells: tryptase- * Correspondence: [email protected] positive MCT cells and tryptase/chymase double-positive 3Division of Rheumatology, Department of Internal Medicine, Research Institute of Medical Science, Konkuk University School of Medicine, 120-1 MCTC cells [3]. MCTC cells can be found in the normal Neungdong-ro, Gwangjin-gu, Seoul 05030, South Korea synovium. The number of MCT cells increases during Full list of author information is available at the end of the article © The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. Kim et al. Arthritis Research & Therapy (2021) 23:124 Page 2 of 13 early RA, indicating tissue inflammation, while that of 16.8 years, rheumatoid factor (RF) 175.8 ± 49.1 IU/L, anti- MCTC cells increases during advanced RA, indicating CCP antibody 462.2 ± 163.2 IU/L, erythrocyte sedimenta- tissue remodeling [4]. tion rage (ESR) 59.6 ± 7.2 mm/h, C-reactive protein (CRP) The role of mast cells in RA is unclear. Some reports 4.5 ± 1.0 mg/dl, DAS28-CRP 4.29 ± 0.2, and disease have demonstrated pathogenic inflammatory roles of duration 2.8 ± 1.7 years. Thirteen patients were not mast cells in RA, while others have shown anti- taking medications, and others were taking oral inflammatory roles of mast cells in RA. Four broad lines disease-modifying antirheumatic drugs (DMARDs). SF of argument have been made for claiming that mast cells was collected from 20 RA patients and 20 patients have an inflammatory role in RA. First, the number of with osteoarthritis of knee joints. All SF samples were mast cells increases in RA synovium and this correlates obtained through therapeutic arthrocentesis before with disease activity parameters [3]. Patients with active steroid injection into the swollen joints. Clinical data RA have more mast cells in synovial tissues than patients of RA patients are as follows: 12 females and 8 males, with end-stage RA [5]. Second, mast cells release various age 53.9 ± 3.2 years, rheumatoid factor (RF) 143.5 ± inflammatory cytokines in RA synovial joints, including 39.3 IU/L, anti-CCP antibody 418.1 ± 155.7 IU/L, ESR interleukin (IL)-6, tumor necrosis factor (TNF)-α, and 51.5 ± 7.8 mm/h, CRP 3.7 ± 1.1 mg/dl, DAS28-CRP 3.8 ± IL-8. Third, histamine and other mast cell mediators 1.1, and disease duration 5.4 ± 1.6 years. Two patients have a potential for angiogenesis, fibroblast and macro- were not taking medications, 1 patient was taking tofaciti- phage activation, osteoclast differentiation, and leukocyte nib, and others were taking oral DMARDs. Synovial recruitment [6–10]. In our previous study, histamine, a tissues were isolated from three RA patients (mean age preformed mediator of activated mast cells, was found to 63.4 ± 4.6 years; range 38–76) and three osteoarthritis stimulate the production of receptor activator of nuclear (OA) patients (mean age 63.5 ± 4.5 years; range 59–68) factor kappa-Β ligand (RANKL) and osteoclast differenti- undergoing total knee-replacement surgery. Informed ation via the histamine H4 receptor [10]. Fourth, mast consent was obtained from all patients. All protocols were cell-deficient animal models are resistant to arthritis performed in accordance with relevant guidelines and reg- [11–13]. In contrast to these arguments, there is also ulations and were approved by the Institutional Review evidence for the anti-inflammatory role of mast cells in Board for Human Research in Konkuk University Hospital RA. First, mast cells suppress monocyte and fibroblast (KUH1010960). activation, dendritic cell migration, and Th1 differenti- ation by inducing the secretion of IL-10, IL-4, IL-13, and Reagents transforming growth factor (TGF)-β [8, 14–16]. Second, Recombinant IL-33, RANKL, and M-CSF were purchased the development of arthritis in animal models is not from R&D systems (Minneapolis, MN). affected by the deficiency of mast cells [17, 18]. Third, serum tryptase levels in RA patients are negatively corre- Human mast cell line culture and stimulation lated with the levels of C-reactive protein [19]. The human mast cell line (LUVA) was purchased from In this study, we aimed to assess the inflammatory and Kerafast (Kerafast, MA, USA) and maintained in tissue-destructive roles of mast cells in RA. We quantified StemPro-34 SFM at a concentration of 5 × 105 cells/ml. the serum and SF concentration of mast cell mediators The cells were grown at 37 °C with 5% CO2, and the such as tryptase, chymase, and histamine in RA patients medium was exchanged weekly with 50% fresh medium and characterized mast cell phenotypes of the mono- without exogenous cytokines. The mast cells were nuclear cells in the SF of RA patients. We also determined seeded in 6-well plates at a density of 5 × 104 cells/ml. the expression and production of proinflammatory After 1 day, the medium was replaced with StemPro-34 cytokines, IL-17, matrix metalloproteinases (MMPs), and SFM culture medium with or without cytokines. The RANKL after stimulating mast cells with IL-33. Finally, we mast cells were then stimulated with 100 ng/mL human examined the effects of activated mast cells on osteoclast recombinant IL-33 (R&D Systems, Inc.) for 24 and 72 h. differentiation in human monocytes. The supernatants and RNA were harvested and stored at − 80 °C until analysis. Methods Ethics statement and patients Enzyme-linked immunosorbent assay (ELISA) Written informed consent was obtained from healthy SF and serum samples obtained from healthy volunteers volunteers and patients with RA and osteoarthritis. All and patients with RA and osteoarthritis were subjected RA patients fulfilled the 2010 ACR/EULAR classification to tryptase, chymase, and histamine analyses using tryp- criteria for RA [20]. Serum was collected from 20 RA tase (Boster Biological Technology, CA), chymase (Aviva patients and 20 healthy volunteers.
Load more

Recommended publications
  • Ncf1 Affects Osteoclast Formation but Is Not Critical for Postmenopausal
    Stubelius et al. BMC Musculoskeletal Disorders (2016) 17:464 DOI 10.1186/s12891-016-1315-1 RESEARCH ARTICLE Open Access Ncf1 affects osteoclast formation but is not critical for postmenopausal bone loss Alexandra Stubelius1*, Annica Andersson1, Rikard Holmdahl3, Claes Ohlsson2, Ulrika Islander1 and Hans Carlsten1 Abstract Background: Increased reactive oxygen species and estrogen deficiency contribute to the pathophysiology of postmenopausal osteoporosis. Reactive oxygen species contribute to bone degradation and is necessary for RANKL- induced osteoclast differentiation. In postmenopausal bone loss, reactive oxygen species can also activate immune cells to further enhance bone resorption. Here, we investigated the role of reactive oxygen species in ovariectomy- induced osteoporosis in mice deficient in Ncf1, a subunit for the NADPH oxidase 2 and a well-known regulator of the immune system. Methods: B10.Q wild-type (WT) mice and mice with a spontaneous point mutation in the Ncf1-gene (Ncf1*/*) were ovariectomized (ovx) or sham-operated. After 4 weeks, osteoclasts were generated ex vivo, and bone mineral density was measured using peripheral quantitative computed tomography. Lymphocyte populations, macrophages, pre-osteoclasts and intracellular reactive oxygen species were analyzed by flow cytometry. Results: After ovx, Ncf1*/*-mice formed fewer osteoclasts ex vivo compared to WT mice. However, trabecular bone mineral density decreased similarly in both genotypes after ovx. Ncf1*/*-mice had a larger population of pre- osteoclasts, whereas lymphocytes were activated to the same extent in both genotypes. Conclusion: Ncf1*/*-mice develop fewer osteoclasts after ovx than WT mice. However, irrespective of genotype, bone mineral density decreases after ovx, indicating that a compensatory mechanism retains bone degradation after ovx.
    [Show full text]
  • Formation of Osteoclast-Like Cells from Peripheral Blood of Periodontitis Patients Occurs Without Supplementation of Macrophage Colony-Stimulating Factor
    J Clin Periodontol 2008; 35: 568–575 doi: 10.1111/j.1600-051X.2008.01241.x Stanley T. S. Tjoa1, Teun J. de Formation of osteoclast-like cells Vries1,2, Ton Schoenmaker1,2, Angele Kelder3, Bruno G. Loos1 and Vincent Everts2 from peripheral blood of 1Department of Periodontology, Academic Centre for Dentistry Amsterdam (ACTA), Universiteit van Amsterdam and Vrije periodontitis patients occurs Universteit, Amsterdam, The Netherlands; 2Department of Oral Cell Biology, Academic Centre for Dentistry Amsterdam (ACTA), without supplementation of Universiteit van Amsterdam and Vrije Universteit, Amsterdam, Research Institute MOVE, The Netherlands; 3Department of Hematology, VUMC, Vrije Universiteit, macrophage colony-stimulating Amsterdam, The Netherlands factor Tjoa STS, de Vries TJ, Schoenmaker T, Kelder A, Loos BG, Everts V. Formation of osteoclast-like cells from peripheral blood of periodontitis patients occurs without supplementation of macrophage colony-stimulating factor. J Clin Periodontol 2008; 35: 568–575. doi: 10.1111/j.1600-051X.2008.01241.x. Abstract Aim: To determine whether peripheral blood mononuclear cells (PBMCs) from chronic periodontitis patients differ from PBMCs from matched control patients in their capacity to form osteoclast-like cells. Material and Methods: PBMCs from 10 subjects with severe chronic periodontitis and their matched controls were cultured on plastic or on bone slices without or with macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor-kB ligand (RANKL). The number of tartrate-resistant acid phosphatase-positive (TRACP1) multinucleated cells (MNCs) and bone resorption were assessed. Results: TRACP1 MNCs were formed under all culture conditions, in patient and control cultures. In periodontitis patients, the formation of TRACP1 MNC was similar for all three culture conditions; thus supplementation of the cytokines was not needed to induce MNC formation.
    [Show full text]
  • Modeling Osteoclast Defect and Altered Hematopoietic Stem Cell Niche in Osteopetrosis with Patient-Derived Ipscs
    Modeling Osteoclast Defect and Altered Hematopoietic Stem Cell Niche in Osteopetrosis with Patient-Derived iPSCs Inci Cevher Zeytin Hacettepe University Berna Alkan Hacettepe University: Hacettepe Universitesi Cansu Ozdemir Hacettepe University: Hacettepe Universitesi Duygu Cetinkaya Hacettepe University: Hacettepe Universitesi FATMA VISAL OKUR ( [email protected] ) Hacettepe University, Faculty of Medicine https://orcid.org/0000-0002-1679-6205 Research Keywords: Osteopetrosis, TCIRG1, iPSC, disease modeling, osteoclast, niche modeling, HSC Posted Date: March 9th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-258821/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/22 Abstract Background Patients with osteopetrosis present with defective bone resorption caused by the lack of osteoclast activity and hematopoietic alterations, but their bone marrow hematopoietic stem/progenitor cell and osteoclast contents might be different. Osteoclasts recently have been described as the main regulators of HSCs niche, however, their exact role remains controversial due to the use of different models and conditions. Investigation of their role in hematopoietic stem cell niche formation and maintenance in osteopetrosis patients would provide critical information about the mechanisms of altered hematopoiesis. We used patient-derived induced pluripotent stem cells (iPSCs) to model osteoclast defect and hematopoietic niche compartments in vitro. Methods iPSCs were generated from peripheral blood mononuclear cells of patients carrying TCIRG1 mutation. iPSC lines were differentiated rst into hematopoietic stem cells-(HSCs), and then into myeloid progenitors and osteoclasts using a step-wise protocol. Then, we established different co-culture conditions with bone marrow-derived hMSCs and iHSCs of osteopetrosis patients as an in vitro hematopoietic niche model to evaluate the interactions between osteopetrotic-HSCs and bone marrow- derived MSCs as osteogenic progenitor cells.
    [Show full text]
  • Survival B Ligand-Induced Osteoclast
    MIP-1γ Promotes Receptor Activator of NF-κ B Ligand-Induced Osteoclast Formation and Survival This information is current as Yoshimasa Okamatsu, David Kim, Ricardo Battaglino, of September 24, 2021. Hajime Sasaki, Ulrike Späte and Philip Stashenko J Immunol 2004; 173:2084-2090; ; doi: 10.4049/jimmunol.173.3.2084 http://www.jimmunol.org/content/173/3/2084 Downloaded from References This article cites 29 articles, 14 of which you can access for free at: http://www.jimmunol.org/content/173/3/2084.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 24, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2004 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology MIP-1␥ Promotes Receptor Activator of NF-␬B Ligand-Induced Osteoclast Formation and Survival1 Yoshimasa Okamatsu,*† David Kim,* Ricardo Battaglino,* Hajime Sasaki,* Ulrike Spa¨te,* and Philip Stashenko2* Chemokines play an important role in immune and inflammatory responses by inducing migration and adhesion of leukocytes, and have also been reported to modulate osteoclast differentiation from hemopoietic precursor cells of the monocyte-macrophage lineage.
    [Show full text]
  • Influence of Iron on Bone Homeostasis
    pharmaceuticals Review Influence of Iron on Bone Homeostasis Enik˝oBalogh 1, György Paragh 2 and Viktória Jeney 1,* 1 Research Centre for Molecular Medicine, Faculty of Medicine, University of Debrecen, 4012 Debrecen, Hungary; [email protected] 2 Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4012 Debrecen, Hungary; [email protected] * Correspondence: [email protected]; Tel.: +36-70-217-1676 Received: 1 September 2018; Accepted: 12 October 2018; Published: 18 October 2018 Abstract: Bone homeostasis is a complex process, wherein osteoclasts resorb bone and osteoblasts produce new bone tissue. For the maintenance of skeletal integrity, this sequence has to be tightly regulated and orchestrated. Iron overload as well as iron deficiency disrupt the delicate balance between bone destruction and production, via influencing osteoclast and osteoblast differentiation as well as activity. Iron overload as well as iron deficiency are accompanied by weakened bones, suggesting that balanced bone homeostasis requires optimal—not too low, not too high—iron levels. The goal of this review is to summarize our current knowledge about how imbalanced iron influence skeletal health. Better understanding of this complex process may help the development of novel therapeutic approaches to deal with the pathologic effects of altered iron levels on bone. Keywords: bone homeostasis; iron overload; iron deficiency; osteoclast; osteoblast; osteoporosis 1. Introduction Bone is a metabolically active tissue that is continuously being remodeled, which enables growth in childhood, as well as repair and adaptation of the skeleton in adults. During bone remodeling, the adult skeleton is renewed approximately once every ten years. The two major cell types involved in bone remodeling are the osteoclasts, with a function of resorption of bone tissue and osteoblasts, with a role of new bone tissue formation.
    [Show full text]
  • Molecular Understanding of Osteoclast Differentiation and Physiology
    Endocrinol Metab 25(4):264-269, December 2010 DOI: 10.3803/EnM.2010.25.4.264 REVIEW ARTICLE Molecular Understanding of Osteoclast Differentiation and Physiology Na Kyung Lee Department of Biomedical Laboratory Science, Soonchunhyang University College of Medical Science, Asan, Korea INTRODUCTION OSTEOCLAST PHYSIOLOGY Two types of cells, osteoblasts and osteoclasts, maintain bone To solubilize the mineral component of bone, osteoclasts form a homeostasis by balancing each other’s function [1,2]. Osteoblasts, resorption space called the sealing zone and make it into an acidic which build bone, are derived from a mesenchymal progenitor cell micro-environment. To do that, cytoskeleton and the integrin of that can also differentiate into marrow stromal cells and adipocytes osteoclast are arranged in a ring for tight attachment to the sub- [3]. Osteoclasts, originating from hemopoietic progenitors of the strate [1]. αVβ3 integrin, an adhesion receptor binding the Arg-Gly- monocyte/macrophage lineage, immigrate into bone via the blood Asp (RGD) motifs of matrix proteins, is essential for normal osteo- stream and resorb mineralized tissues [1,2,4]. Bone through this clast function since mice lacking beta3 integrins fail to spread or continuous dynamic remodeling provides structural integrity, skel- form sealing zones, thus becoming osteosclerotic [7]. Similarly, etal strength, and a reservoir for hematopoiesis. Elevated osteoclast mice deficient in src, a ubiquitously expressed non-receptor tyro- numbers and activity cause osteoporosis, Paget’s disease, tumor sine kinase display osteopetrosis characterized by dysfunctional osteolysis, various arthritis, and periodontal disease. These dis- osteoclasts with abnormal sealing zones and αVβ3 localization [8,9]. eases result in low bone mass and high fracture risk, which can Of note, αVβ3 integrin and c-Fms, the receptor of M-CSF, collabo- also occur as a result of an osteoblast defect.
    [Show full text]
  • Osteoblast Retraction Induced by Adherent Neutrophils
    Laboratory Investigation (2011) 91, 905–920 & 2011 USCAP, Inc All rights reserved 0023-6837/11 $32.00 Osteoblast retraction induced by adherent neutrophils promotes osteoclast bone resorption: implication for altered bone remodeling in chronic gout Isabelle Allaeys1, Daniel Rusu1, Sylvain Picard2, Marc Pouliot1, Pierre Borgeat1 and Patrice E Poubelle1 Bone destruction in chronic gout is correlated with deposits of monosodium urate (MSU) crystals. Bone with MSU tophi were histopathologically shown to have altered remodeling and cellular distribution. We investigated the impact of neutrophils in bone remodeling associated with MSU and demonstrated that neutrophils, through elastase localized at their surface, induced retraction of confluent osteoblasts (OBs) previously layered on calcified matrix. This OB retraction allowed osteoclasts to resorb cell-free areas of the matrix. This neutrophil effect was concentration dependent and time dependent and required direct contact with OBs. Exposure of OBs to MSU greatly promoted neutrophil adherence to OBs. Neutrophil membrane at the contact zone with OBs showed concentrated fluorescence of dye PKH-67, indicating a cellular contact. Neutrophil–OB interaction increased the survival of neutrophils, reduced their release of lactoferrin in presence of MSU and did not change OB-mediated mineralization. The adhesion of neutrophils to OBs was heterotypic through neutrophil CD29/CD49d and OB-fibronectin peptide CS1. Leukotriene B4 (LTB4) and platelet-activating factor (PAF) were also involved in neutrophil adherence to OBs, as shown by the blocking effect of selective LTB4 and PAF receptor antagonists, and a cytosolic phospholipase A2a (cPLA2a) inhibitor. Blockade of CD49d/CS1 and inhibition of the cPLA2a had subadditive effects, reducing by 60% the adherence of neutrophils to OBs.
    [Show full text]
  • Human Osteoclast Formation and Bone Resorption by Monocytes And
    816 Ann Rheum Dis 1996;55:816-822 Human osteoclast formation and bone resorption Ann Rheum Dis: first published as 10.1136/ard.55.11.816 on 1 November 1996. Downloaded from by monocytes and synovial macrophages in rheumatoid arthritis Y Fujikawa, A Sabokbar, S Neale, N A Athanasou Abstract and macrophages.3'- Both intimal and subin- Objective-To determine whether syno- timal synovial macrophages in rheumatoid vial macrophages and monocytes isolated arthritis are derived from the circulation, blood from patients with rheumatoid arthritis monocytes passing through the tall endothe- patients are capable ofdifferentiating into lium ofpostcapillary venules to enter the syno- osteoclastic bone resorbing cells; and the vial tissues.'0 cellular and humoral conditions required Macrophages rather than T cells have been for this to occur. found to predominate at the articular margins Methods-Macrophages isolated from the where there is bone and cartilage destruc- synovium and monocytes from the tion." 1 A significant correlation has been peripheral blood of rheumatoid arthritis reported between the degree of joint erosion patients were cultured on bone slices and and the number of synovial macrophages." At coverslips, in the presence and absence of the site of marginal erosions, bone resorption, UMR 106 rat osteoblast-like cells, however, appears to be effected largely by rec- 1,25-dihydroxy vitamin D3 (1,25(0H)2D3) ognisable osteoclasts.'"' Various macrophage and macrophage colony stimulating factor derived cytokines are known to enhance osteo- (M-CSF), and assessed for cytochemical clastic bone resorption indirectly (through and functional evidence of osteoclast osteoblast stimulation)'5 and several of these differentiation.
    [Show full text]
  • Aberrant Bone Homeostasis in AML Is Associated with Activated Oncogenic FLT3-Dependent Cytokine Networks
    cells Article Aberrant Bone Homeostasis in AML Is Associated with Activated Oncogenic FLT3-Dependent Cytokine Networks 1, 2, 3 3,4 5, Isabel Bär y, Volker Ast y, Daria Meyer , Rainer König , Martina Rauner z, 5, , 1, , Lorenz C. Hofbauer * z and Jörg P. Müller * z 1 Institute of Molecular Cell Biology, Center for Molecular Biomedicine (CMB), Jena University Hospital, 07745 Jena, Germany; [email protected] 2 Institute for Clinical Chemistry, Medical Faculty Mannheim, Heidelberg University, 69117 Heidelberg, Germany; [email protected] 3 Center for Infectious Diseases and Infection Control, Jena University Hospital, 07745 Jena, Germany; [email protected] (D.M.); [email protected] (R.K.) 4 Integrated Research and Treatment Center, Center for Sepsis Control and Care (CSCC), 07745 Jena, Germany 5 Department of Medicine III & Center for Healthy Aging, Technical University Dresden, 01069 Dresden, Germany; [email protected] * Correspondence: [email protected] (L.C.H.); [email protected] (J.P.M.); Tel.: +49-351-458-3173 (L.C.H.); +49-364-1939-5634 (J.P.M.) These authors joined first. y These authors equally contributed. z Received: 5 October 2020; Accepted: 5 November 2020; Published: 9 November 2020 Abstract: Acute myeloid leukaemia (AML) is a haematopoietic malignancy caused by a combination of genetic and epigenetic lesions. Activation of the oncoprotein FLT3 ITD (Fms-like tyrosine kinase with internal tandem duplications) represents a key driver mutation in 25–30% of AML patients. FLT3 is a class III receptor tyrosine kinase, which plays a role in cell survival, proliferation, and differentiation of haematopoietic progenitors of lymphoid and myeloid lineages.
    [Show full text]
  • Osteoclast-Associated Intracellular Itam Signalling Molecules in Human Peri-Implant Osteolysis and Rheumatoid Arthritis
    OSTEOCLAST-ASSOCIATED INTRACELLULAR ITAM SIGNALLING MOLECULES IN HUMAN PERI-IMPLANT OSTEOLYSIS AND RHEUMATOID ARTHRITIS Ekram Alias BSc. (Biomedical Sc.), BHSc. (Hons.) DISCIPLINE OF ANATOMY AND PATHOLOGY SCHOOL OF MEDICAL SCIENCES Thesis submitted for the Doctor of Philosophy in Medicine in The School of Medical Sciences at The University of Adelaide November 2013 TABLE OF CONTENTS ! TABLE!OF!CONTENTS...................................................................................................................... i! ABSTRACT.........................................................................................................................................vi! STATEMENT!OF!ACCESS ............................................................................................................ viii! DECLARATION!OF!ORIGINALITY ...............................................................................................ix! ACKNOWLEDGEMENT.................................................................................................................... x! PUBLICATIONS ...............................................................................................................................xii! SCIENTIFIC!COMMUNICATIONS .............................................................................................. xiii! ABBREVIATIONS...........................................................................................................................xvi! LIST!OF!FIGURES...........................................................................................................................xix!
    [Show full text]
  • Potentiation of Osteoclast Bone-Resorption Activity by Inhibition of Nitric Oxide Synthase (Bone Ceil/Nitric Oxide/Aminguanidine) THOMAS P
    Proc. Nati. Acad. Sci. USA Vol. 91, pp. 3569-3573, April 1994 Pharmacology Potentiation of osteoclast bone-resorption activity by inhibition of nitric oxide synthase (bone ceil/nitric oxide/aminguanidine) THOMAS P. KASTEN*, PATRICIA COLLIN-OSDOBYt, NiRAJ PATELt, PHILIP OSDOBYt, MARILYN KRUKOWSKIt, THOMAS P. MISKO*, STEVEN L. SETTLE*, MARK G. CURRIE*, AND G. ALLEN NICKOLS*t§ *Department of Molecular Pharmacology, Monsanto Corporate Research, St. Louis, MO 63167; tDepartment of Biology and Division of Bone and Mineral Diseases, Washington University, St. Louis, MO 63130; and tDepartment of Pharmacological and Physiological Sciences, St. Louis University Medical School, St. Louis, MO 63104 Communicated by Philip Needleman, December 27, 1993 ABSTRACT We have examined the effects of modulating histochemical level, Schmidt et al. (11) have demonstrated nitric oxide (NO) levels on osteoclast-mediated bone resorption that nitric oxide synthase (NOS) was present in areas ofbone in vitro and the effects ofnitric oxide synthase (NOS) inhibitors coincident with osteoclast and bone-remodeling activity. The on bone mineral density in vivo. Diaphorase-based histochem- report of MacIntyre et al. (12) indicated that NO-generating ical staining for NOS activity of bone sections or highly agents caused a decrease in isolated rat osteoclast cell spread enriched osteoclast cultures suggested that osteoclasts exhibit area and bone resorption. Also, Howard (13) reported that substantial NOS activity that may account for basal NO NO-generating compounds may increase cGMP levels in production. Chicken osteoclasts were cultured for 36 hr on isolated chicken osteoclasts. Furthermore, sodium nitroprus- bovine bone slices in the presence or absence of the NO- side (SNP) has been shown to inhibit the parathyroid hor- generating agent sodium nitroprusside or the NOS inhibitors mone or 1,25-(OH)2-vitamin D3 stimulation of resorption in N-nitro-L-arginine methyl ester and aminoguanidine.
    [Show full text]
  • Platelet-Rich Plasma Inhibits RANKL-Induced Osteoclast Differentiation Through Activation of Wnt Pathway During Bone Remodeling
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 41: 729-738, 2018 Platelet-rich plasma inhibits RANKL-induced osteoclast differentiation through activation of Wnt pathway during bone remodeling DONGYUE WANG*, YAJUAN WENG*, SHUYU GUO*, YUXIN ZHANG, TINGTING ZHOU, MENGNAN ZHANG, LIN WANG and JUNQING MA Jiangsu Key Laboratory of Oral Diseases, Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China Received February 7, 2017; Accepted November 2, 2017 DOI: 10.3892/ijmm.2017.3258 Abstract. Platelet-rich plasma (PRP) is used in the clinic as protein 1 and β-catenin. The results of the present study an autologous blood product to stimulate bone regeneration indicated that PRP inhibits osteoclast differentiation through and chondrogenesis. Numerous studies have demonstrated activation of the Wnt pathway. that PRP affects bone remodeling by accelerating osteo- blast formation. With the research perspective focusing on Introduction osteoclasts, the present study established a mouse model of mandibular advancement to examine the effect of PRP Angle class II malocclusion is a common condition that pres- on osteoclast differentiation induced by modification of ents most commonly as mandibular retrusion (1). Treatment the dynamics of the temporomandibular joint (TMJ). The of this condition involves the use of functional appliances lower incisors of the mice were trimmed by 1 mm and the to stimulate mandibular growth by forward posturing of the resultant change in mandibular position during the process mandible. During this process, a series of morphological and of eating induced condylar adaptation to this change. PRP histological changes are observed in the region of the temporo- significantly increased the bone mass and decreased osteo- mandibular joint (TMJ), which manifest as reconstruction of clastic activity, in vitro as well as in vivo.
    [Show full text]